PURE Bioscience Reports Fiscal First Quarter 2026 Financial Results
Company Overview
PURE Bioscience, Inc. (OTCQB: PURE) (“PURE,” the “Company,” “we,” or “our”) is the creator of a patented, non-toxic antimicrobial based on silver dihydrogen citrate (SDC). The Company develops and commercializes innovative sanitation and antimicrobial solutions designed to improve safety, efficiency, and sustainability across multiple industries, including produce, beverage, dairy, and transportation. PURE today reported its financial and operating results for the fiscal first quarter ended October 31, 2025.
Financial Performance Highlights
During the fiscal first quarter of 2026, PURE delivered continued improvement in its financial performance, highlighted by year-over-year revenue growth and a reduced net loss. The Company’s results reflect increased adoption of its products by existing customers, expanding market penetration, and disciplined cost management.
Net product sales for the fiscal first quarter ended October 31, 2025, were $707,000, compared to $555,000 for the same period in the prior fiscal year. This represents an increase of $152,000, or approximately 27%, driven primarily by higher sales volumes across the Company’s end-user customer base. Growth was supported by increased demand in core markets and expanding relationships with distribution partners.
Net Loss and Profitability Trends
Net loss for the fiscal first quarter ended October 31, 2025, was $464,000, compared to a net loss of $689,000 for the fiscal first quarter ended October 31, 2024. The $225,000 year-over-year improvement reflects higher revenues and ongoing efforts to manage operating expenses while continuing to invest in growth initiatives.
Excluding share-based compensation, net loss for the fiscal first quarter ended October 31, 2025, was $430,000, compared to $632,000 for the comparable period in fiscal 2024. This improvement demonstrates progress toward the Company’s longer-term objective of reaching profitability through revenue growth and operating leverage.
Net loss per share was ($0.00) for the fiscal first quarter ended October 31, 2025, compared to ($0.01) per share for the fiscal first quarter ended October 31, 2024. The improvement in per-share results reflects both reduced net loss and changes in the Company’s share base.
Operational Progress and Market Expansion
As an update to the Company’s press release dated October 29, 2025, PURE is pleased to report continued momentum across its key target markets. The Company has made significant progress in expanding its presence within the produce industry, which remains a core focus of its growth strategy.
Sales of PURE Control®, the Company’s seasonal direct food-contact solution, continued to grow during the quarter. Importantly, PURE Control® is now actively being used to treat leafy greens destined for commercial sale. This milestone represents a meaningful step forward in market adoption and reflects growing customer confidence in the safety, efficacy, and regulatory readiness of PURE’s SDC-based technology.
In addition to produce, the Company has experienced increased traction in the transportation industry. PURE has leveraged its new SDC-powered sanitation technology and related equipment offerings through key distribution partners to reach major trucking fleets. These solutions are designed to address sanitation and biosecurity needs in transportation environments, providing an additional avenue for revenue diversification and long-term growth.
Product Innovation and Strategic Initiatives
PURE continues to invest in the development and rollout of new applications for its SDC-based antimicrobial technology. During the fiscal first quarter, the Company worked closely with distribution partners in the beverage and dairy industries to advance the deployment of new membrane treatment solutions. These initiatives are intended to expand PURE’s addressable market and deepen its relationships with large-scale industrial customers.
The Company remains focused on converting successful product evaluations and trials into long-term customer relationships. Management believes that continued demonstration of product performance, combined with strong distributor partnerships, will support sustained revenue growth over time.
Management Commentary
Jeff Kitchell, President of PURE Bioscience, commented on the quarter’s results, stating:
“Our fiscal first quarter year-over-year sales growth shows the progress we have made with our direct customers and distribution network. We are continuing to grow our core produce business, which remains a key driver of our revenue. At the same time, we are working closely with our distribution partners in the beverage and dairy industry to roll out our new membrane treatment solutions. We believe these efforts position the Company well for continued growth as adoption of our SDC-based technologies expands.”
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that do not describe historical facts, including statements regarding the Company’s expectations, plans, business outlook, future performance, potential revenues, anticipated results of marketing efforts, execution of contracts under negotiation, and assumptions regarding future events or conditions, are forward-looking statements.
Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Factors that could cause or contribute to such differences include, but are not limited to, the Company’s ability to implement its business initiatives; market acceptance of its current and future products; the Company’s ability to convert evaluations and trials into customer orders; customer retention and expansion of product usage; maintenance of relationships with partners and counterparties;
the Company’s ability to generate sufficient revenue and manage expenses to achieve profitability; access to required financing; development of new products and receipt of necessary regulatory approvals; competitive pressures, including pricing considerations; reliance on third-party manufacturers and vendors; and other risks described in the Company’s filings with the Securities and Exchange Commission, including its Form 10-K for the fiscal year ended July 31, 2025, and Form 10-Q for the fiscal first quarter ended October 31, 2025.
Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to update or revise any forward-looking statements as a result of new information, future events, or otherwise.
Source Link : https://www.businesswire.com/
